---
title: "Exozymes Raises $5.95 Million in Underwritten Equity Offering Led by MDB Capital"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290107775.md"
description: "Exozymes completed a $5.95 million underwritten equity offering led by MDB Capital, selling units at $18.00. The company issued shares and warrants, with proceeds allocated to R&D, commercialization of NCT, and working capital. Exozymes appointed VStock Transfer as warrant agent and granted underwriter warrants to MDB Capital."
datetime: "2026-06-17T21:13:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290107775.md)
  - [en](https://longbridge.com/en/news/290107775.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290107775.md)
generator: "portal-rs"
---

# Exozymes Raises $5.95 Million in Underwritten Equity Offering Led by MDB Capital

Exozymes completed a firm commitment underwritten equity offering led by MDB Capital, selling units priced at $18.00, each consisting of two shares and one warrant. The company initially issued 592,270 shares and 296,135 warrants, and MDB later exercised a portion of the over-allotment for 34,440 additional units, bringing total gross proceeds to approximately $5.95 million. Exozymes also executed a Warrant Agent Agreement with VStock Transfer to administer investor warrants and entered into an Underwriter’s Warrant Agreement providing warrants to the underwriter. Proceeds will support development and commercialization of N-trans-caffeoyltyramine (NCT), additional product opportunities, R&D, and working capital.

**Agreement 1: Exozymes Enters Underwriting Agreement for $5.95 Million Equity Offering With MDB Capital**

-   **Agreement type**: Underwriting agreement for firm commitment equity offering (units of two shares and one warrant)
-   **Counterparty**: MDB Capital
-   **Signed / Effective**: Jun 05 2026 / Jun 05 2026
-   **Duration / Termination**: At will
-   **Reason**: Raise capital to fund development, R&D, and operations

**Agreement 2: Exozymes Appoints VStock Transfer as Warrant Agent for Equity Offering**

-   **Agreement type**: Warrant Agent Agreement covering investor warrants from public offering
-   **Counterparty**: VStock Transfer
-   **Signed / Effective**: Jun 05 2026 / Jun 05 2026
-   **Duration / Termination**: At will
-   **Reason**: Administer and service public offering warrants

**Agreement 3: Exozymes Issues Underwriter Warrants in Connection With MDB-Led Offering**

-   **Agreement type**: Underwriter’s Warrant Agreement
-   **Counterparty**: MDB Capital
-   **Signed / Effective**: Jun 09 2026 / Jun 09 2026
-   **Duration / Termination**: At will
-   **Reason**: Provide customary underwriter compensation for the offering

Original SEC Filing: EXOZYMES INC. \[ EXOZ \] - 8-K - Jun. 17, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [EXOZ.US](https://longbridge.com/en/quote/EXOZ.US.md)
- [MDBH.US](https://longbridge.com/en/quote/MDBH.US.md)

## Related News & Research

- [EXOZ: NCT program exceeded targets; $6M raised and $2M NIH grant secured for R&D and commercialization](https://longbridge.com/en/news/296532185.md)
- [Guardian Metal Resources PLC Announces Warrant Exercise | GMTL Stock News](https://longbridge.com/en/news/296090846.md)
- [REG - Sareum Holdings PLC - Exercise of Warrants](https://longbridge.com/en/news/296362927.md)
- [ReNew Energy Global warrants set to be delisted after expiration](https://longbridge.com/en/news/296360098.md)
- [REG - Neoterra Group PLC - Extension of 2p Warrants to 9 October 2026](https://longbridge.com/en/news/296512113.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**